Claims for Patent: 9,765,399

Summary for Patent: 9,765,399

Title:	Mutations in the epidermal growth factor receptor gene
Abstract:	The invention relates to a new identified mutation in the epidermal growth factor receptor gene, leading to an amino acidic change which highly correlates with the resistance to a therapy regimen comprising cetuximab and the sensitivity to a therapy regimen comprising panitumumab. The invention includes peptide sequences, primers and probes to detect such a mutation, as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab and/or panitumumab. In particular, the invention is useful in the therapy regimen applicable to metastasic colorectal cancer and to head and neck cancer.
Inventor(s):	Montagut Viladot; Clara (Barcelona, ES), Albanell Mestres; Joan (Barcelona, ES), Rovira Guerin; Ana (Barcelona, ES), Bellosillo Paricio; Beatriz (Barcelona, ES), Dalmases Masseg ; Alba (Barcelona, ES)
Assignee:	FUNDACIO INSTITUT MAR D\'INVESTIGACIONS MEDIQUES (IMIM) (Barcelona, ES)
Application Number:	14/236,614
Patent Claims:	1. An in vitro method of predicting the response of a subject therapy regimen comprising cetuximab and/or panitumumab, wherein the method comprises: i) determining the presence or absence of an arginine at position 492 of the amino acid sequence corresponding to SEQ ID NO: 8 in a sample taken from the subject by one or more of: genotype methods, and/or protein sequencing methods; wherein this determining includes amplifying a genomic region comprising SEQ ID NO: 8 of the EGFR coding region with a set of primers including one or more primers consisting of one or both SEQ ID Nos: 3 (gggacctccggtcagaaaa) and 4 (cggtgacttactgcagctgttt); ii) correlating the presence of the arginine identified in step i) with resistance of the subject to the therapy regimen comprising cetuximab, or correlating the absence of the arginine identified in step i) with response of the subject to the therapy regimen comprising panitumumab. 2. The in vitro method according to claim 1, wherein the subject is affected with cancer. 3. The in vitro method according to claim 2, wherein the cancer is selected from the group consisting of metastasic colorectal cancer and head and neck cancer. 4. An in vitro method of identifying the presence of an arginine in the EGFR gene encoding the amino acid of SEQ ID NO: 10 in a sample taken from a subject, comprising identifying the amino acid at position 492 of SEQ ID NO: 10 as arginine by one or more genotype methods, wherein the one or more genotype methods comprise providing an oligonucleotide that is specific for a codon encoding an arginine at position 492. 5. The in vitro method according to claim 4, wherein the oligonucleotide is a probe oligonucleotide having a sequence of SEQ ID NO: 5. 6. The in vitro method according to claim 4, wherein the one or more genotype methods comprise one or both of PCR or a real time PCR.

Details for Patent 9,765,399

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-08-03
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2031-08-03
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2031-08-03